Chinese Medicine for Heart: Merck’s $2B Deal
Merck to Acquire Rights to Experimental Heart Drug
Table of Contents
- Merck to Acquire Rights to Experimental Heart Drug
- Merck’s Investment in Experimental Heart Drug: A Q&A
- What is Merck’s Recent Investment in a Heart Drug?
- What is the Focus of This Experimental Heart Drug?
- How Much Did Merck Pay Upfront, and What Are the Potential Future Payments?
- What Phase of Clinical Trials is the Drug Currently In?
- Who Are Merck’s Competitors in This Area?
- Why Is Merck Investing in China for drug Development?
- How Dose This Investment Affect Merck’s Market Performance?
- Key Details of Merck’s Investment
Merck & Co. will pay up to $2 billion for the rights to an experimental heart drug, marking the second recent investment by the American pharmaceutical company in China for a novel medication.
According to the agreement, Merck will pay $200 million upfront to develop adn market the drug, which is currently in the intermediate phase of clinical trials in humans. Merck has promised another $1.77 billion, contingent on regulatory and commercial milestones, along with royalties for sales. The developing company will retain the rights to the medication within the Chinese market.
the agreement follows Merck’s December proclamation of a $2 billion licensing deal for a potential obesity treatment.Global pharmaceutical companies are increasingly looking to China to bolster their pipelines, as the country’s burgeoning biotechnology sector has created a breeding ground for novel medications at competitive prices.
The experimental drug, blocks lipoprotein (a), a blood protein that, like some forms of cholesterol, is linked to cardiovascular diseases. Eli Lilly & Co., Amgen Inc., and Novartis AG are among other pharmaceutical companies developing therapies targeting the same protein.
Merck’s shares fell 0.4% at the start of trading in the American stock market. They have decreased 7.2% so far this year through Monday.
Scientists Develop Modified Bacteria to Fight Tumors with Infrared light
A team of researchers has engineered an intelligent control system in genetically modified bacteria to precisely and safely target tumors, activated by near-infrared light (NIR).This advancement could significantly improve the effectiveness of bacterial cancer therapies by enabling localized and regulated delivery of anti-cancer drugs.
The study, published in the journal Nature Cancer, involved scientists who designed an optogenetic system called Netmap (Near-Infrared Light-Mediated Padc-Based Photoswitch), which allows for controlled gene expression in bacteria upon exposure to infrared light.
The bacteria used in the study where modified to contain a biological switch
based on the PADC protein, which responds to NIR light and triggers the production of anti-cancer drugs directly at the tumor site.
This method offers advantages over conventional therapies by allowing for precise dose control and reduced adverse effects.
Preclinical models in mice showed that the application of the Netmap system in lymphoma, colon cancer, and breast cancer tumors resulted in tumor reduction of up to 80%.
Trials using patient-derived xenografts (PDX) demonstrated a significant inhibition of tumor growth and an increase in the death of cancer cells.
The Effects of Infrared Light
According to researchers, near-infrared light has high penetration in biological tissues, which facilitates the activation of modified bacteria without invasive procedures.
Furthermore, the researchers genetically modified the cancer-fighting bacteria strains to improve their safety, eliminating toxicity-associated genes without affecting their ability to colonize tumors.
The research team is currently collaborating with a hospital to evaluate the clinical viability of this technology.
experts say that the next steps will include expanding studies to other types of cancer, such as melanoma and breast cancer, with the goal of moving toward human trials.
Recently, researchers have also developed artificial intelligence tools to improve early detection of esophageal cancer and have introduced medical isotope production devices for high-precision cancer treatments.
Merck’s Investment in Experimental Heart Drug: A Q&A
What is Merck’s Recent Investment in a Heart Drug?
Merck & Co. is investing in a new experimental heart drug,signaling the company’s increased focus on novel medications. The total investment could reach up to $2 billion. This marks Merck’s second recent major investment in China for a new drug.
What is the Focus of This Experimental Heart Drug?
The drug targets lipoprotein (a), or Lp(a), a blood protein linked to cardiovascular diseases. this protein is similar to some forms of cholesterol and is considered a risk factor for heart attacks and strokes.
How Much Did Merck Pay Upfront, and What Are the Potential Future Payments?
Merck initially paid $200 million to develop and market the drug. The company has also committed an additional $1.77 billion, which will be paid out contingent on meeting regulatory and commercial milestones, along with royalties on sales. The developing company will retain rights to the medication within the Chinese market.
What Phase of Clinical Trials is the Drug Currently In?
The drug is currently in the intermediate phase of clinical trials in humans, which is Phase 2.
Who Are Merck’s Competitors in This Area?
Other major pharmaceutical companies, including Eli Lilly & Co., Amgen Inc., and Novartis AG, are also developing therapies targeting the same protein, Lp(a).
Why Is Merck Investing in China for drug Development?
Global pharmaceutical companies, like Merck, are increasingly looking to China to bolster their drug pipelines. China’s biotechnology sector is rapidly growing, creating an environment conducive to the development of new medications at competitive prices.
How Dose This Investment Affect Merck’s Market Performance?
At the start of trading on the American stock market, Merck’s shares decreased by 0.4%. The shares have seen a decrease of 7.2% so far this year.
Key Details of Merck’s Investment
| Feature | Details |
| :————————— | :——————————————————————- |
| Initial Investment | $200 million |
| Potential Total Investment | Up to $2 billion |
| Drug Target | Lipoprotein (a), a protein linked to cardiovascular diseases |
| Clinical Trial Phase | Phase 2 |
| Other Companies Involved | Eli Lilly & Co., Amgen Inc., Novartis AG (also developing similar drugs) |
| Focus of Investment | Experimental heart drug |